Core Points - Ole Palmå will leave his position as CEO of Brøndby IF in 2026 to become the new commercial director at DBU [1] - The board of Brøndby IF has initiated the process of finding a new CEO [1] - Ole Palmå will transfer his responsibilities with the aim of departing in the first quarter of the new year [1]

Core Points - Realkredit Danmark will conduct auctions for mortgage covered bonds series 10F and 11F on December 23, 2025, due to remortgaging activities starting January 1, 2026 [1] - The final amounts for the auctions will be announced on the auction day via Bloomberg's chat system around 9:00 a.m. [2] - The auction terms and conditions are detailed in the appendix of the announcement [3] Sales Expectations - An increase in bond sales is anticipated, with expected sales as follows: - FlexLån® (other maturities, January): DKK 400 million - FlexLån® (other maturities, April): DKK 400 million - Other floating rate loans: DKK 150 million - Fixed rate loans: DKK 300 million [4] - A total of DKK 6.30 billion, including auction amounts, is expected to be sold [5] - Realkredit Danmark is not obligated to sell the entire announced amount of bonds [6]

Financial Calendar - The Board of Directors of TCM Group A/S has announced key dates for the publication of interim and annual reports, as well as the annual general meeting for 2026 [1] - Interim report Q4 2025 and Annual report 2025 will be published on 26 February 2026 [1] - The annual general meeting is scheduled for 9 April 2026 [1] - Subsequent interim reports for Q1, Q2, and Q3 of 2026 will be published on 21 May, 20 August, and 19 November respectively [1] - The annual report for 2026 will be published on 25 February 2027, with the next annual general meeting on 7 April 2027 [1] Company Overview - TCM Group is the third largest manufacturer of kitchens and furniture for bathrooms and storage in Scandinavia [2] - The company designs and produces its products in Denmark, emphasizing quality and craftsmanship [2] - TCM Group operates a multi-brand strategy, with the main brand being Svane Køkkenet, alongside Tvis Køkken, Nettoline, and AUBO [2] - The brands cater to a wide price spectrum and are sold through approximately 220 dealers in Denmark and Scandinavia [2] - TCM Group also sells private label kitchens through DIY stores in Denmark and independent kitchen stores in Norway [2]

Core Points - Nordea Funds Ltd. has reduced its holding in Solar A/S to 4.96% of the voting rights after selling shares on December 17, 2025, totaling 78,788,600 shares at DKK 100 each [1] Company Overview - Solar A/S is a leading European sourcing and services company focused on electrical, heating and plumbing, ventilation, climate, and energy solutions [2][3] - The company generated approximately DKK 12.2 billion in revenue in 2024 and employs around 2,900 people [3] - Solar A/S is listed on Nasdaq Copenhagen under the designation SOLAR B [3] Business Focus - The company emphasizes efficiency improvement and provides digital tools to enhance customer success [3] - Solar A/S is committed to driving the green transition and offers best-in-class solutions for sustainable resource use [3]

Group 1 - The company has announced the convening of its Annual General Meeting scheduled for January 21, 2026 [1]

Core Viewpoint - Alvotech and Teva Pharmaceuticals have reached a settlement with Regeneron Pharmaceuticals regarding the launch of AVT06, a proposed biosimilar to Eylea, allowing for potential U.S. market entry in Q4 2026, pending FDA approval [1][2]. Group 1: Product Development and Approval - AVT06 has received marketing approval as a biosimilar to aflibercept in the UK, Japan, and 30 countries within the European Economic Area [3]. - A confirmatory clinical study demonstrated that AVT06 met its primary endpoint, showing high similarity in efficacy, safety, and immunogenicity compared to Eylea in patients with neovascular age-related macular degeneration [4]. Group 2: Strategic Partnerships and Market Positioning - The settlement positions Alvotech and Teva favorably for a successful U.S. launch of AVT06, following recent approvals in Europe and Japan [2]. - Alvotech aims to be a global leader in the biosimilar market, with a pipeline that includes eight disclosed biosimilar candidates targeting various diseases [8].

Group 1 - Virtune, a regulated digital asset manager based in Sweden, has launched the Virtune Bittensor ETP on Nasdaq Stockholm, marking its 21st product offering [1][5] - The Virtune Bittensor ETP is a physically backed exchange-traded product designed to provide investors with secure and cost-effective exposure to Bittensor (TAO) [2][8] - The ETP offers 1:1 exposure to Bittensor, is 100% physically backed by TAO, and has an annual management fee of 1.95% [8] Group 2 - Bittensor is a decentralized network that facilitates the development of artificial intelligence through an open marketplace, rewarding participants based on the value of their contributions [4] - The launch of the Virtune Bittensor ETP is seen as a strategic expansion in the Nordic market, catering to both institutional and retail investors [5][6]

Financial Results Schedule - The company will publish its unaudited results for Q4 2025 and the full year 2025 on 06 February 2026 [1] - Audited results for 2025, along with a dividend proposal and agenda for the Annual General Meeting of Shareholders, will be released on 27 March 2026 [1] - Financial results for Q1 2026 are scheduled for 08 May 2026 [1] - Financial results for Q2 2026 will be published on 31 July 2026 [1] - The company will announce its financial results for Q3 2026 on 30 October 2026 [1] Annual General Meeting - The Annual General Meeting of Shareholders is set to take place on 23 April 2026 [1]

Company Overview - Guerbet is a global leader in medical imaging, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging [5] - The company has been a pioneer in contrast agents for 98 years and employs 2,905 people worldwide [6] - Guerbet dedicated 9% of its revenue to Research & Development across four centers in France and the United States [6] - In 2024, Guerbet achieved €841 million in revenue [6] Appointment of François Convenant - François Convenant has been appointed as Senior Vice President of Interventional Radiology and will join the Guerbet Group's Executive Committee [1] - He joined Guerbet in September 2018 and has extensive international experience in the healthcare and medical device sector [2] - His previous roles involved management positions at leading companies, focusing on innovation and growth in surgical solutions and interventional devices [2] Interventional Radiology Insights - Interventional radiology is a rapidly expanding medical specialty that combines advanced imaging with minimally invasive therapeutic procedures [3] - This field is experiencing rapid growth due to an aging population and increasing demand for less invasive treatments [3] - Technological innovations, including AI, robotics, and precision imaging, are enhancing the safety and effectiveness of procedures [3] - The economic and clinical impact includes reduced costs related to complications and improved quality of life for patients [4] Guerbet's Mission and Offerings - Guerbet aims to meet the needs of healthcare institutions and practitioners by providing integrated and innovative solutions [4] - The company combines drugs, medical devices, services, and technologies, supported by dedicated training programs to enhance clinical practices [4]

Core Insights - Sai Life Sciences Limited released its Sustainability Report for 2024–25, focusing on "Driving climate action, deepening stakeholder trust" and aligning with GRI and SASB standards [1][2] Sustainability Strategy - The company's sustainability strategy is based on nine strategic pillars: water stewardship, climate action, circularity, biodiversity, sustainable procurement, human capital, governance and ethics, community engagement, and customer co-creation [2][3] - These pillars integrate sustainability into all operational stages, aligning with business objectives and stakeholder expectations [2] Sustainable Development Goals - Sai Life Sciences has defined Sustainable Development Goals (SDGs) to meet its sustainability commitments by March 31, 2027, with ongoing progress in greenhouse gas reduction and renewable energy usage [3][4] - The API manufacturing unit in Bidar is powered by 96% renewable energy, and the company has reduced specific water consumption across its facilities [3] Community Impact - The company exceeded its commitment to provide education and livelihood opportunities for 8,000 individuals from underprivileged communities, demonstrating significant community impact [3] Workforce Diversity - The organization has seen steady growth in diversity, with women representing 14% of the workforce [3] Long-term Vision - The 2024–25 Sustainability Report reflects the company's long-term view, emphasizing science, responsibility, and collaboration as central to its growth ambitions [4]